Estrella achieves CR in patient treated with CD19-redirected ARTEMIS T-cells

Estrella Immunopharma announced that the first patient enrolled in its STARLIGHT-1 Phase I/II clinical trial has achieved a complete response one month after receiving an infusion of EB103 CD19- Redirected ARTEMIS T Cells. In a clinical trial, a complete response means that no detectable signs of disease or cancer remain after treatment. The patient, diagnosed with follicular lymphoma grade 3A with high-risk 3B symptoms, was enrolled in the STARLIGHT-1 trial at UC Davis Comprehensive Cancer Center and received EB103 therapy after relapsing three times following prior treatments. Given the patient’s high tumor burden and multiple comorbidities, the patient was considered at high-risk, which might have increased the severity of side effects like cytokine release syndrome and neurotoxicity with commercially available CAR-T treatments. However, no treatment-related serious adverse events were observed in this case. “We are cautiously optimistic about these early results and the favorable safety profile of EB103 observed in our first treated patient of this clinical trial,” said Cheng Liu, Ph.D., President and CEO of Estrella Immunopharma. “Our goal is to develop ARTEMIS T-cell therapies that not only match but also surpass the efficacy of commercially available CAR-T therapies, while also addressing their safety shortcomings. By improving safety, we hope to reach a broader patient population and make T-cell therapy accessible in community hospitals, not just specialized cancer centers.” The Phase I/II STARLIGHT-1 clinical trial is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of EB103 autologous T-cell therapy and to determine the Recommended Phase II Dose in adult subjects who have relapsed/refractory B-cell NHL. The study includes a dose escalation phase followed by an expansion phase.